Fundraising FoxCyllene Therapeutics
Paris, FR · 8 known investors
Find your way into Cyllene Therapeutics
Sign up to see every warm intro you have to Cyllene Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Cyllene Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Cyllene Therapeutics is a biotechnology company developing "pinpoint gene therapy" using a non-replicative HSV-1 based vector platform to deliver disease-modifying transgenes for peripheral nervous system disorders. Its lead asset, EG110A, is in clinical development for neurogenic detrusor overactivity (neurogenic bladder dysfunction).
Founders & leadership
Investors · 8
How we know: the company's own site · funding news · pharmaceutical-technology.com · Not right? Tell us
How we know: M Ventures's portfolio page · globenewswire.com · Not right? Tell us
How we know: SCI Ventures's portfolio page · Not right? Tell us
How we know: a partner's Signal profile · funding news · globenewswire.com · Not right? Tell us
Also in the syndicate · 4
Funding
SEC filings, press & company announcements$37M disclosed across 1 round · 2026
- $37MSeries CJul 2026 · 5 sources
GordonMD Global Investments (lead), GordonMD Global Investments® LP (lead), M Ventures (lead), Merck KGaA's venture arm (lead), Andera Partners SAS, Bpifrance Investissement, Lamond Ventures LLC
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Cyllene Therapeutics do?
- Cyllene Therapeutics is a biotechnology company developing "pinpoint gene therapy" using a non-replicative HSV-1 based vector platform to deliver disease-modifying transgenes for peripheral nervous system disorders. Its lead asset, EG110A, is in clinical development for neurogenic detrusor overactivity (neurogenic bladder dysfunction).
- Who founded Cyllene Therapeutics?
- Cyllene Therapeutics was founded by Philippe Chambon MD, PhD.
- Who are Cyllene Therapeutics's investors?
- Cyllene Therapeutics's investors include Bpifrance, M Ventures, SCI Ventures, Andera Partners.
- How much funding has Cyllene Therapeutics raised?
- Cyllene Therapeutics has disclosed $37M raised across 1 round.
- Where is Cyllene Therapeutics headquartered?
- Cyllene Therapeutics is headquartered in Paris, FR.